

CANADIAN UROLOGICAL ASSOCIATION

62nd Annual Meeting • Québec City, QC • June 24-27, 2006

Sunday, June 24

- 11:00-12:00 Exhibit opening/Brunch/Poster display
- 12:00-12:10 Welcome from the Scientific programme chairs
Fred Saad, Montréal, QC; Stéphane Bolduc, Québec, QC
- 12:10-12:40 RCPSC Address: Progress in the use of PSA in clinical practice**
Speaker: *William Catalona, Chicago, IL*
Chair: *Fred Saad, Montréal, QC*
- 12:40-13:40 Podium Session 1: Prostate Cancer**
Chairs: *Armen Aprikian, Montréal, QC; Martin Gleave, Vancouver, BC*
- 12:40-12:50 PD01.01 Assessing individual risk for prostate cancer
Robert Nam, Toronto, ON
- 12:50-13:00 PD01.02 Mortality at 120 days after prostatic biopsy: a population-based study of 22175 men
Quoc-Dien Trinh, Montréal, QC
- 13:00-13:10 PD01.03 Nomogram predicting 10 year life expectancy after radical prostatectomy or radiation therapy for prostate cancer
Claudio Jeldres, Montréal, QC
- 13:10-13:20 PD01.04 Natural history of untreated prostate cancer; cohort of 186 men with 5 years follow up
Mohammed F. Al Otaibi, Montréal, QC
- 13:20-13:30 PD01.05 30-day mortality after radical prostatectomy in over 9000 patients: validation of a predictive nomogram
Quoc-Dien Trinh, Montréal, QC
- 13:30-13:40 PD01.06 Comparing PSA triggers for treatment for men with prostate cancer on active surveillance
Andrew Loblaw, Toronto, ON
- 13:40-14:10 CUASF Address: Bladder cancer screening and innovative therapies: a 20-year quest ready for prime time?**
Speaker: *Yves Fradet, Québec, QC*
Chair: *Laurence Klotz, Toronto, ON*
- 14:10-14:40 Break in Exhibit Hall/Poster display
- 14:40-15:30 Podium Session 2: Prostate Cancer**
Chair: *Michael Chetner, Edmonton, AB*
- 14:40-14:50 PD02.01 High surgical volume is associated with lower rate of secondary therapies after radical prostatectomy for localized prostate cancer
Claudio Jeldres, Montréal, QC
- 14:50-15:00 PD02.02 Androgen deprivation therapy is associated with high prevalence of metabolic syndrome and diabetes mellitus
Hassan Razvi, London, ON
- 15:00-15:10 PD02.03 Androgen deprivation therapy for prostate cancer treatment: the role of the time of exposure on the risk of bone fractures
Pierre Karakiewicz, Montréal, QC
- 15:00-15:10 PD02.04 Disease outcome of patients with a psa ≥ 20 ng/ml treated by radical prostatectomy: analysis of 185 patients
Frédéric Pouliot, Québec, QC
- 15:10-15:20 PD02.05 Clinical T3 prostate cancer treated with radical prostatectomy: pathological and long-term outcomes
Paul Perrotte, Montréal, QC
- 15:20-15:30 PD02.06 Salvage therapy with bicalutamide 150 mg in patients with PSA failure under LHRH therapy or surgical castration for advanced prostate cancer
Yves Fradet, Québec, QC
- 15:30-16:00 Invited Lecture: Management of high risk localized and locally advanced prostate cancer**
Speaker: *Anthony d'Amico, Boston, MA*
Chair: *Neil Fleshner, Toronto, ON*
- 16:00-16:50 Educational Forum 1: Oncology**
Chair: *Robert Nam, Toronto, ON*
Panel: *William Catalona, Chicago, IL; Anthony d'Amico, Boston, MA; Fred Saad, Montréal, QC*
- 18:00 Welcome reception, Parliament Building, Québec National Assembly

Monday, June 25

- 7:00-7:50 Industry-sponsored symposium. Sanofi-Aventis Canada: Optimizing Treatment Management of Advanced Prostate Cancer through a Multidisciplinary Approach
- 8:00-8:50 Industry-sponsored symposium. Bayer Inc. PDE5i: ED and beyond
- 9:00-10:30 Moderated Posters 1: Prostate Cancer**
Chairs: *Anthony d'Amico, Boston, MA; Laurence Klotz, Toronto, ON*
- MP01.01 High volume provider is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer
Claudio Jeldres, Montréal, QC

MP01.03 Age is an independent predictor of bone metastasis in patients diagnosed with prostate cancer
Claudio Jeldres, Montréal, QC

MP01.04 Pre-operative staging of prostate cancer using surface-coil magnetic resonance imaging
Rodney Breau, Ottawa, ON

MP01.05 Prediction of prostate cancer in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation
Moamen Amin, Montréal, QC

MP01.06 Outcome of repeat transrectal ultrasound prostate biopsy positive patients with HPIN and/or ASAP
Darwin Lim, London, ON

MP01.07 Risk of prostate cancer detection on repeat transrectal ultrasound guided biopsy
Mazen Abdelhady, London, ON

MP01.08 MRI directed trans-rectal ultrasound biopsies in patients at risk for prostate cancer
Jean-Baptiste Lattouf, Montréal, QC

MP01.09 Impact of extended prostate biopsy on minimization of the volume-grade bias in prostate cancer detection
Abdullah Al-Ghamdi, Toronto, ON

MP01.10 Impact of negative re-biopsy in a cohort of prostate cancer patients managed with watchful waiting
Mohammed Al Otaibi, Montréal, QC

MP01.11 Second treatment rates in prostate cancer patients treated for cure in the USA and Canada
Jun Kawakami, Kingston, ON

MP01.12 Drivers of treatment selection in prostate cancer patients treated for cure in an American database and a Canadian database
Jun Kawakami, Kingston, ON

MP01.13 A cross sectional study of health related quality of life (HRQOL) in men treated with radical prostatectomy or external beam radiotherapy for localized prostate cancer
Mazen Abdelhady, London, ON

MP01.14 Health related quality of life (HRQOL) outcome after salvage cryosurgery of the prostate: comparison with outcome after primary radiotherapy
Mazen Abdelhady, London, ON

9:00-10:30 Moderated Posters 2: Male Health

Chairs: *François Bénard, Montréal, QC; John Grantmyre, Halifax, NS*

MP02-01 In vivo brain-derived neurotrophic factor (BDNF) expression and timing patterns in aged rats following cavernous nerve axotomy
Anthony Bella, San Francisco, CA

MP02-02 Early experience with the new AMS 700™ with MS pump™ series inflatable penile prosthesis
Anthony Bella, San Francisco, CA

MP02-03 Potential mechanisms for erectile rehabilitation after radical prostatectomy: indirect effect of sildenafil on neurite outgrowth
Anthony Bella, San Francisco, CA

MP02-04 Liquid microparticle delivery of intracavernous growth differentiation factor-5 therapy enhances the recovery of erectile function in a rat model of cavernous nerve injury
Anthony Bella, San Francisco, CA

MP02-05 Comparison of Kruger strict morphology among fertile and infertile males
Ethan Grober, Houston, TX

MP02-06 Extracorporeal shock-wave lithotripsy is not supported by evidence-based medicine for first-line treatment of Peyronie's disease
Anthony Bella, San Francisco, CA

MP02-07 Relationship between sperm DNA fragmentation and sperm density, motility, and abnormal morphology
Bryce Weber, Toronto, ON

MP02-09 The effect of male testosterone replacement therapy on untreated female partners: a pilot study
Mohit Khera, Houston, TX

MP02-10 Testosterone is a better indicator than prolactin in predicting a pituitary microadenoma in patients with hyperprolactinemia
Mohit Khera, Houston, TX

MP02-11 The safety and efficacy of testosterone replacement therapy following radical prostatectomy
Mohit Khera, Houston, TX

MP02-12 Should patients with decreased prolactin levels be screened differently for prostate cancer?
Mohit Khera, Houston, TX

MP02-13 Biopsychosocial factors in quality of life in men with chronic prostatitis/chronic pelvic pain syndrome
J. Curtis Nickel, Kingston ON

MP02-14 80 W potassium-titanyl-phosphate (KTP) laser photoselective vaporization prostatectomy (PVP) for symptomatic benign prostatic hyperplasia (BPH)
Carson Wong, Oklahoma City, OK

MP02-15 Holmium laser enucleation of the prostate (HoLEP): long-term results
Ehab Elzayat, Montréal, QC

9:00-10:30 Moderated Posters 3: Miscellaneous Topics

Chairs: *Mireille Grégoire, Québec, QC; Kirk Lo, Toronto, ON*

MP03-01 One year follow up of autologous muscle derived cell injection to treat stress urinary incontinence
Lesley Carr, Toronto, ON

MP03-02 Peer reviewed publications by the CUA membership: then and now
Andrew MacNeily, Vancouver, BC

- MP03-03 HATS: health advocacy in training survey
Michael Leveridge, Kingston, ON
- MP03-04 Percutaneous nephrolithotripsy for staghorn calculus: a single centre's experience
Frédéric Soucy, London, ON
- MP03-05 Clinical and radiographic factors predicting shock wave lithotripsy (SWL) success: a view to a nomogram
Trevor Schuler, Toronto, ON
- MP03-06 Long term indwelling catheters: an RCT of catheter flush vs standard care
Chasta Bacsu, Edmonton, AB
- MP03-07 Long-term surgical outcomes of ileocystoplasty with continent abdominal stoma
David Hajek Provost, Toronto, ON
- MP03-08 Dyspareunia response in interstitial cystitis patients treated with intravesical lidocaine, bicarbonate, and heparin
Blayne Welk, Vancouver, BC
- MP03-09 urethrovaginal fistula repair: long-term experience
Sender Herschorn, Toronto, ON
- MP03-10 Treatment-related improvement in sleep disturbances in patients with interstitial cystitis/painful bladder syndrome (IC/PBS)
J. Curtis Nickel, Kingston, ON
- MP03-11 Analysis of videourodynamic results and the utility of leak point pressure as a measure for intrinsic sphincter deficiency in women with stress urinary incontinence
Sender Herschorn, Toronto, ON
- MP03-12 The Effects of Triclosan on uropathogen sensitivity to clinically relevant antibiotics
Geoffrey Wignall, London, ON
- MP03-13 Assessment and correlation of urinary symptoms and urodynamic findings in multiple sclerosis patients: do they correlate?
Sidney Radomski, Toronto, ON
- 10:30-11:00 Break in Exhibit Hall/Poster display
- 11:00-11:15 CUA Historical Lecture: Emasculation: a history of castration**
Speaker: *Ian Davis, Hamilton, ON*
- 11:15-11:25 AUA Address**
Speaker: *Paul Schellhammer, Norfolk, VA*
- Introduction: Luc Valiquette, Montréal QC**
- 11:25-11:55 Invited Lecture: Botulinum toxin A: the 21st century penicillin for the bladder**
Speaker: *Clare Fowler, London, UK*
Chair: *Jacques Corcos, Montréal, QC*
- 12:00-13:00 Lunch in Exhibit Hall/Poster display
- 13:00-13:50 Podium Session 3: Renal Cancer and Minimally Invasive Surgery**
Chairs: *Michael Jewett, Toronto, ON; Joseph Chin, London, ON*
- 13:00-13:10 PD03.01 Robot-assisted laparoscopic radical prostatectomy at a Canadian institution: initial experience at the University of Western Ontario
Geoffrey Wignall, London, ON
- 13:10-13:20 PD03.02 The natural history of small renal masses: a prospective multi-center Canadian trial
Kamal Mattar, Toronto, ON
- 13:20-13:30 PD03.04 Watchful waiting strategy for selected patients with renal masses: updated results and long-term follow up
T. Abou Youssif, Montréal, QC
- 13:30-13:40 PD03.05 Teaching laparoscopic radical prostatectomy in academic and private hospitals: the mentored approach
Edward Matsumoto, McMaster University, Hamilton, ON
- 13:50-14:20 Invited Lecture: Small renal mass—current concepts and management**
Speaker: *Inderbir Gill, Cleveland, OH*
Chair: *Anthony Finelli, Toronto, ON*
- 14:20-14:50 Break in Exhibit Hall/Poster display
- 14:50-15:20 Invited Lecture: What stays up must come down: surgery for the undescended testicle**
Speaker: *Steven Docimo, Philadelphia, PA*
Chair: *Michael Leonard, Ottawa, ON*
- 15:20-16:10 Podium Session 4: Pediatric Urology**
Chairs: *John-Paul Capolicchio, Montréal, QC; Karen Psooy, Winnipeg, MB*
- 15:20-15:30 PD04.01 Competence in pediatric urology upon graduation from residency: perceptions of residents, program directors and pediatric urologists
Andrew MacNeily, Vancouver, BC
- 15:30-15:40 PD04.02 Failed pyeloplasty in children: comparative analysis of retrograde endopyelotomy vs. re-do pyeloplasty
Luis H.P. Braga, Toronto, ON
- 15:40-15:50 PD04.03 Blunt renal trauma in a tertiary pediatric trauma center: management, outcome and complications
Luis Guerra, Ottawa, ON
- 15:50-16:00 PD04.04 Laparoscopic extravesical ureteral reimplantation in children
John-Paul Capolicchio, Montréal, QC
- 16:00-16:10 PD04.05 Prospective comparative study of poly-methylsiloxane vs hyaluronic acid injection for treatment of vesicoureteral reflux
Katherine Moore, Québec, QC
- 15:20-17:20 Moderated Posters 4: Basic Science**
Chairs: *Alan So, Vancouver, BC; William Catalona, Chicago, IL*

MP04.01 Dendritic cells pulsed with bladder tumor promote anti-tumor effects
Jonathan Izawa, London, ON

MP04.02 Over-expression of iKkε induces inflammatory cytokine expression in hormone-dependent prostate cancer cells
Benjamin Péant, Montréal, QC

MP04.03 Targeting chemoresistant prostate cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin
Boris Hadaschik, Vancouver, BC

MP04.04 C-reactive protein is the foremost predictor of renal cell carcinoma-specific mortality: a study of 313 patients
Quoc-Dien Trinh, Montréal, QC

MP04.05 Novel markers of aggressiveness in renal cell carcinoma generated from an in vitro model
Jean-Baptiste Lattouf, Montréal, QC

MP04.06 VHL gene mutations in sporadic renal cell carcinoma
Kamal Mattar, Toronto, ON

MP04.07 Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival in patients with renal cell carcinoma (RCC)
Quoc-Dien Trinh, Montréal, QC

MP04.08 Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression
Robert Nam, Toronto, ON

MP04.09 Reduction of the cytosolic Cdk11 protein expression in clear cell renal cell carcinoma
Anil Kapoor, Hamilton, ON

MP04.10 Tn expression in localized high-risk prostate cancer
Alain Bergeron, Québec, QC

MP04.11 MAGE-A4 and MAGE-A9 protein expression in renal cell carcinoma
Valérie Picard, Québec, QC

MP04.12 Lower plasma adiponectin levels as a potential biomarker for renal cell carcinoma: an update on a continuing study
B. Tisdale, Hamilton, ON

MP04.13 High Ki67 expression is associated, in a multi-variate model, with lower risk of biochemical recurrence in prostate cancer patients following radical prostatectomy
Philippe Gannon, Montréal, QC

MP04.14 The role of stimulatory ligand expression on prostate cancer cells and evasion of immune effector cell killing
D. Robert Siemens, Kingston, ON

MP04.15 Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human superficial bladder cancer
Cherifa Ayari, Québec, QC

MP04.16 Low nuclear androgen receptor expression in prostate cancer predicts an early onset of biochemical recurrence
Jean-Simon Diallo, Montréal, QC

MP04.17 ErbB4 nuclear localization, gamma-secretase and neuregulin expression in prostate cancer: multi-variate analysis of prostate cancer patient clinical outcome
Ismaël-Hervé Koumakpayi, Montréal, QC

MP04.18 Effect of androgen deprivation on PSP94 expression in prostate cancer cells
Mazen Abdelhady, London, ON

15:20-17:20 Moderated Posters 5: Miscellaneous Oncology
Chairs: *Rabi Tiguert, Québec, QC; Jonathan Izawa, London, ON*

MP05.01 Differentiation of renal tumors by diffusion-weighted MRI: utility of the apparent diffusion coefficient
Matei Andreoiu, Winnipeg, MB

MP05.02 A phase I/II study of Vicinium™ given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: phase I final results
Nicola Jones, Mississauga, ON

MP05.03 Prognostic risk factors for progression in clinical stage I nonseminomatous testicular germ cell tumors managed by surveillance
David Kakiashvili, Toronto, ON

MP05.04 Outcomes of extravesical tumor extension (pT3) in pathological staging of bladder cancer following radical cystectomy
Guilherme Godoy, Vancouver, BC

MP05.05 Disease free and overall survival worse in elderly patients with upper tract urothelial carcinoma despite lower stage disease
Stephanie Snow, Halifax, NS

MP05.07 Clinical relevance of incidental prostate cancer at radical cystoprostatectomy for urothelial carcinoma
Nader Fahmy, Montréal, QC

MP05.08 Partial cystectomy for bladder cancer in Québec: a population-based study
Nader Fahmy, Montréal, QC

MP05.09 Cystectomy: time and treatment factors affecting tumour progression
Paul Johnston, Kingston, ON

MP05.10 Treatment of BCG failed non muscle invasive bladder cancer (NMIBC) with intravesical bacille Calmette-Guérin (BCG) and interferon-α2B (IFN) combination therapy
P. Jacob John, Halifax, NS

MP05.11 Cost effectiveness of immediate cystectomy versus BCG for the treatment of high risk T1G3 bladder cancer
Girish Kulkarni, Toronto, ON

- MP05.12 Immediate cystectomy versus conservative management with delayed cystectomy for high risk T1G3 bladder cancer: a decision analysis
Girish Kulkarni, Toronto, ON
- MP05.13 Bone density in patients with prostatic adenocarcinoma treated with GnRHa – a prospective cohort study
Avi Andrew Ray, London, ON
- MP05.14 Zoledronic acid reduces bone loss from goserelin acetate treatment in men with prostate cancer
Richard Casey, Oakville, ON
- MP05.15 Patterns and detection of relapse in clinical stage I nonseminomatous germ cell testis tumors on surveillance: recommendations for follow-up
David Kakiashvili, Toronto, ON
- 16:10-17:00 Educational Forum 2: Pediatric Urology**
Chair: *Stéphane Bolduc, Québec, QC*
Panelists: *Steven Docimo, Philadelphia, PA; Andrew MacNeily, Vancouver, BC; Armando Lorenzo, Toronto, ON*
- 18:00-21:00 CUA Fun Night, Quebec Convention Centre
- Tuesday, June 26**
- 7:00-7:50 Industry-sponsored symposium. GlaxoSmithKline Inc. Risk reduction in Canadian men. . . the role of 5ARIs in BPH and prostate cancer: an interactive forum,
- 8:00-8:50 Industry-sponsored symposium. Abbott: Prostate cancer challenging cases: nomograms vs. clinicians
- 9:00-9:15 Monday poster highlights
- 9:15-10:05 Podium Session 5: LUTS and Incontinence**
Chairs: *J. Curtis Nickel, Kingston, ON; Mostafa Elhilali, Montréal, QC*
- 9:15-9:25 PD05.01 The adjustable continence therapy (ACT®) system: preliminary results of the North America ACT clinical study group
Maude Carmel, Sherbrooke, QC
- 9:25-9:35 PD05.02 Prevalence of overactive bladder: Canadian results from the EPIC study
Sender Herschorn, Toronto, ON
- 9:35-9:45 PD05.03 Male sling for moderate to severe stress urinary incontinence: efficacy and mechanism
Bechir Hage, Sherbrooke, QC
- 9:45-9:55 PD05.04 Prevalence of lower urinary tract symptoms (LUTS) in men: Canadian results from the EPIC study
Sender Herschorn, Toronto, ON
- 9:55-10:05 PD05.05 Finasteride monotherapy maintains stable urinary symptoms (IPSS) in men newly diagnosed with benign prostatic hyperplasia for 9 months after 9 months of combination therapy using both an alpha-blocker and finasteride
J. Curtis Nickel, Kingston, ON
- 10:05-10:35 Break in Exhibit Hall/Poster display
- 10:35-11:05 Invited Lecture: Neurogenic bladders**
Speaker: *Emmanuel Chartier-Kastler, Paris, France*
Chair: *Luc Valiquette, Montréal, QC*
- 11:05-11:55 Educational forum 3: Urinary Incontinence**
Chair: *Le Mai Tu, Sherbrooke, QC*
Panelists: *Jacques Corcos, Montréal, QC; Emmanuel Chartier-Kastler, Paris, France; Kevin Carlson, Vancouver, BC*
- 12:00-13:00 Lunch in Exhibit Hall/Poster display
- 12:00-14:00 CUA Annual General Meeting
- 14:00-14:40 Podium Session 6: Renal Cancer**
Chairs: *Christopher Morash, Ottawa, ON; Robert Siemens, Kingston, ON*
- 14:00-14:10 PD06.01 A multidisciplinary clinic for metastatic renal cell carcinoma: a streamlined approach to care
Stephen Pautler, London, ON
- 14:10-14:20 PD06.02 Prediction of the probability of metastatic disease after nephrectomy for renal cell carcinoma: validation of a multi-institutional nomogram
Quoc-Dien Trinh, Montréal, QC
- 14:20-14:30 PD06.03 Surgical experience with renal cell carcinoma and inferior vena cava thrombus
Julie Franc-Guimond, Montréal, QC
- 14:30-14:40 PD06.04 A multicenter, randomized, phase 3 trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma
Simon Tanguay, Montréal, QC
- 14:40-15:30 Educational Forum 4: Renal Cancer**
Chair: *Pierre Karakiewicz, Montréal, QC*
Panelists: *Anil Kapoor, Hamilton, ON; Michael Jewett, Toronto, ON; Paul Perrotte, Montréal, QC; Eric Winquist, London, ON*
- 15:30-17:30 Moderated posters 6: Pediatric Urology**
Chairs: *Dawn MacLellan, Halifax, NS; Peter Metcalfe, Edmonton, AB*
- MP06.01 Construction of a tissue engineered genitourinary tubular tissue graft
Martine Magnan, Québec, QC
- MP06.02 In vitro construction of a tissue engineered autologous vesical graft by the self-assembly method
Emilie Perron, Québec, QC
- MP06.03 Partial nephrectomy: does retroperitoneoscopy adversely affect postoperative residual size & function?
Julie Franc-Guimond, Montréal, QC
- MP06.04 Factors influencing the outcome of primary hypospadias repair
Katherine Moore, Québec, QC

- MP06.05 Bladder mass after renal transplantation in children
F. Almodhen, Montréal, QC
- MP06.06 The “incidental anaesthetic”: an opportunity for the endoscopic management of vesicoureteric reflux
John-Paul Capolicchio, Montréal, QC
- MP06.07 Management of pediatric urethral strictures: a review of our experience
Gaayana Raju, Ottawa, ON
- MP06.08 Comparative analysis of tubularized incised plate vs. onlay island flap urethroplasties for penoscrotal hypospadias
Luis HP Braga, Toronto, ON
- MP06.09 Complications of the catheterizable channel following continent urinary diversion: their nature and timing
Blayne Welk, Vancouver, BC
- MP06.10 Peri-conceptual folic acid use in Nova Scotia
Andrea Lantz, Halifax, NS
- MP06.11 Spongioplasty facilitates postoperative catheterization, if required after non-stented tubularized incised urethral plate (TIP) repair of primary hypospadias
F. Almodhen, Montréal, QC
- MP06.12 Intravesical oxybutynin for children with poorly compliant neurogenic bladders: a systematic review
Luis Guerra, Ottawa, ON
- MP06.13 Long-term functional outcome and satisfaction of patients with hypospadias repaired in childhood
Christopher Hoag, Vancouver, BC
- MP06.14 Factors associated with mortality in children with Wilms’ tumor
Jean-Philippe Drolet, Québec, QC
- MP06.15 Critical appraisal of the role of ureteroscopy in treatment of pediatric renal and ureteric calculi
Sumit Dave, Toronto, ON
- MP06.16 Foreskin reconstruction in hypospadias surgery: does our practice reflect parental expectation in North America?
Sumit Dave, Toronto, ON

15:30-17:30 Moderated Posters 7: Renal Cancer

Chairs: *Simon Tanguay, Montréal, QC;*
Anil Kapoor, Hamilton, ON

- MP07.01 Initial assessment of a screening tool for renal tumor therapy sensitivity using ex vivo invasion assay
Yves Caumartin, London, ON
- MP07.02 The prognostic ability of simplified nuclear grading of renal cell carcinoma
Quoc-Dien Trinh, Montréal, QC
- MP07.03 Anaemia and thrombocytosis do not change the ability to predict renal cell carcinoma (RCC)

specific survival: an analysis of 1828 patients
Quoc-Dien Trinh, Montréal, QC

MP07.04 Partial nephrectomy using renal artery perfusion for cold ischemia: functional and oncologic outcomes.
Jean-Baptiste Lattouf, Montréal, QC

MP07.05 Increasing tumor size is associated with increasing nuclear grade in patients with renal cell carcinoma
Elie Antebi, Montréal, QC

MP07.06 A nomogram predicting renal cell carcinoma-specific survival in patients with nodal metastases is more accurate than any individual variable
Elie Antebi, Montréal, QC

MP07.07 Tumor histology is not a predictor of renal cell carcinoma-specific survival in patients with metastatic renal cell carcinoma
Elie Antebi, Montréal, QC

MP07.08 Presence of systemic symptoms is the foremost predictor of mortality in patients with exclusive nodal metastases
Georg-Christoph Hutterer, Montréal, QC

MP07.09 Presence and type of renal cell carcinoma (RCC) related symptoms predict RCC-specific survival after nephrectomy in patients with either nodal or distant metastases
Georg-Christoph Hutterer, Montréal, QC

MP07.10 Follow-up regimens after radical or partial nephrectomy for localized renal cell carcinoma
Kamal Mattar, Toronto, ON

MP07.11 Early detection of renal cell carcinoma in asymptomatic patients improves cancer-specific survival in all stages
Claudio Jeldres, Montréal, QC

MP07.12 Management of metastatic renal cell carcinoma (MRCC) with tyrosine kinase inhibition (TKI) sorafenib and sunitinib – clinical experience and toxicity management
Anil Kapoor, Hamilton, ON

MP07.13 Cytoreductive nephrectomy in patients with metastatic renal cell cancer: impact of different clinicopathological factors on survival
T. Abou Youssif, Montréal, QC

MP07.14 Preservation of renal function after partial nephrectomy when compared with radical nephrectomy
Aaron Clark, Ottawa, ON

MP07.15 Dietary habits, genitourinary tract infection and prostate cancer prediction
Moamen Amin, Montréal, QC

MP07.16 Protective effects of non-steroidal anti-inflammatory drugs on prostate cancer progression: a population-based study
D. Robert Siemens, Kingston, ON

15:30-17:30 Moderated Posters 8: Transplantation and Minimally Invasive Surgery

Chairs: *Inderbir Gill*, Cleveland, OH; *Paul Whelan*, Hamilton, ON

MP08.01 Safety of penile prosthesis for the treatment of erectile dysfunction in solid-organ transplant patients

Anthony Bella, San Francisco, CA

MP08.02 Impact of arterial and arteriovenous renal clamping with and without intrarenal cooling on renal oxygenation and temperature in a porcine model

Alexandra Perks, Toronto, ON

MP08.03 Ability of carbon monoxide releasing molecules to protect against transplant-related injury

Yves Caumartin, London, ON

MP08.04 Outcomes comparison between third kidney re-transplant versus mate primary transplant

Yves Caumartin, London, ON

MP08.05 Accurate prediction of delayed graft function after renal transplantation based on recipient weight and cold ischemia time

Quoc-Dien Trinh, Montréal, QC

MP08.06 Immunological and surgical outcomes of extra-capsular vs intra-capsular allograft nephrectomies

Yves Caumartin, London, ON

MP08.07 Laparoscopic partial nephrectomy (LPN) with six-year follow-up. Intraoperative ultrasound necessary for oncologic success?

Anil Kapoor, Hamilton, ON

MP08.08 Laval University experience of 100 cases of laparoscopic pyeloplasties: no difference between primary and non-primary pyeloplasty success rates

Frédéric Pouliot, Québec, QC

MP08.09 Robot-assisted laparoscopic radical prostatectomy: single surgeon learning curve at a Canadian institution

Geoffrey Wignall, London, ON

MP08.10 A single institution experience with laparoscopic radical prostatectomy for high risk prostate cancer patients

Ashis Chawla, Hamilton, ON

MP08.11 comparative analysis of transperitoneal and retroperitoneal laparoscopic partial nephrectomies reveals that retroperitoneal approach leads to shorter hospital stay

Frédéric Pouliot, Québec, QC

MP08.12 Validated visual grading system for nerve-sparing laparoscopic radical prostatectomy

Omar Nazif, Edmonton, AB

MP08.13 Laparoscopic extraperitoneal radical prostatectomy: experience at a small Canadian community hospital with 100 cases

Bernard Bukala, Stratford, ON

MP08.14 Laparoscopic partial nephrectomy: functional and oncologic outcomes with up to 6 years followup
Jean-Baptiste Lattouf, Montréal, QC

19:00-23:00 President's Banquet, Hilton QC

Wednesday, June 27

7:00-7:50

Industry-sponsored symposium. Merck Frosst Canada Ltd: Optimizing Prostate Health: Practical take-aways from PCPT and MTOPS in the prevention, screening, and treatment of LUTS-BPH and early prostate cancer.

8:00-8:15

Tuesday poster highlights

8:15-9:00

Invited Lecture: The role of nutrition in prostate cancer prevention

Speaker: *Richard Béliveau*, Québec, QC

Chair: *Fred Saad*, Québec, QC

9:00-9:50

Educational Forum 5: Endourology/Stones

Chair: *Tim Wollin*, Edmonton, AB

Panelists: *Kenneth Pace*, Toronto, ON;

Ben Chew, Vancouver, BC; *Denis Hosking*,

Winnipeg, MB

9:50-10:30

Podium Session 7: Outcomes

Chairs: *Jean-François Audet*, Québec, QC

9:50-10:00

PD07.01 Success of erectile dysfunction treatment in men after radical prostatectomy, radiation therapy or both for prostate cancer

Sidney Radomski, Toronto, ON

10:00-10:10

PD07.02 Examination of the relationship between prostate inflammation, clinical prostatitis-like symptoms, BPH-related lower urinary tract symptoms and sexual dysfunction: baseline data from the REDUCE trial

J. Curtis Nickel, Kingston ON

10:10-10:20

PD07.03 Impact of treatment delay in bladder cancer patients managed with partial cystectomy in Québec: a population-based study

Nader Fahmy, Montréal, QC

10:20-10:30

PD07.04 Non risk-adapted surveillance management for clinical stage I nonseminomatous testis tumors

David Kakiashvili, Toronto, ON

10:45-11:35

Educational Forum 6: Infertility/Vasectomy

Chair: *Peter Chan*, Montréal, QC

Panelists: *Armand Zini*, Toronto, ON;

Kirk Lo, Toronto, ON; *Claude Martin, Jr.*,

Ottawa, ON

11:35-11:45

Final Farewell

12:00-18:00

CUA Golf Tournament, La Tempête Golf Club at Breakeyville